News | Prostate Cancer | August 16, 2016

European observational study finds improved mortality at hospitals with highest percentage of radiotherapy and/or prostatectomy

high-risk prostate cancer, radical local treatment, Umea University Sweden study, mortality

August 16, 2016 — High-risk prostate cancer patients treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy) only have half of the mortality risk of men treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden and published in European Urology.

"The results suggest that the combination of thorough examination and subsequent radical local therapy can prolong life for men with very high-risk prostate cancer," said Pär Stattin, a researcher at the Department of Surgical and Perioperative Sciences, who led the study.

Using patient data from the National Prostate Cancer Register (NPCR) of Sweden, the researchers investigated the link between prostatectomy or full-dose radiotherapy and mortality in men with deadly high-risk prostate cancer. Differences in treatment selection were analyzed on a group basis, whereas mortality from prostate cancer and other causes was analyzed on an individual basis.

Results show that men with a very high-risk prostate cancer, who were treated at hospitals with the highest proportion of radical treatment, were only half as likely (mortality rate ratio; MRR 0.51) to die from prostate cancer compared to men treated at hospitals where radical local therapy was administered the least. However, since this was an observational study, the potential effects of high-intensity in diagnostic activity and work-up cannot be isolated from therapeutic activity.

"Our data suggests that there are benefits of radical local therapy for men with very advanced forms of prostate cancer. However, these men most often only receive hormonal treatment. To confirm our findings and hopefully to improve treatment praxis, there is a need for a randomized study of the effects of local radical therapy on patients with very high-risk prostate cancer," said Stattin.

For more information: www.europeanurology.com


Related Content

News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Oct. 8, 2026 — DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., has announced new findings published in ...

Time October 13, 2026
arrow
News | Artificial Intelligence

Sept. 29, 2026 — A recently published study shows that using artificial intelligence to track which pathologies ...

Time October 01, 2026
arrow
News | Stereotactic Body Radiation Therapy (SBRT)

Sept. 27, 2026 — Siemens Healthineers recently launched Accela, a radiotherapy solution engineered around NeoArc ...

Time October 01, 2026
arrow
News | Digital Pathology

Sept. 24, 2026 — Leica Biosystems,has added two Paige digital pathology AI-enabled products from Tempus to its Aperio AI ...

Time September 25, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | CT Angiography (CTA)

Sept. 15, 2026 — A new study published in the Journal of the American College of Radiology (JACR) found that an ...

Time September 15, 2026
arrow
News | Lung Imaging

Sept. 8, 2026 – Brainomix and Endeavor BioMedicines recently presented positive results from the Brainomix AI-driven ...

Time September 09, 2026
arrow
News | Ultrasound Imaging

Sept. 2, 2026 – Sonex Health and The Institute of Advanced Ultrasound Guided Procedures have announced publication of ...

Time September 04, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
Subscribe Now